FINAL_LOGO-02.jpg
New U.S. Patent Allowance Granted To Axim® Biotechnologies For Anti-Microbial Compositions Comprising Cannabinoids
08 août 2019 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today...
FINAL_LOGO-02.jpg
AXIM® Biotechnologies Featured in Bloomberg Law for Robust Cannabinoid-Based Patent Portfolio
06 août 2019 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today...
FINAL_LOGO-02.jpg
AXIM® Biotechnologies Launches AXIM® Wellness Division Focused on Cannabinoid-Based Nutraceutical Products and Announces New Product Pipeline
30 juil. 2019 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, July 30, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today...
FINAL_LOGO-02.jpg
AXIM® Biotechnologies Receives Seventh Private Label Gum Purchase Order Pushing Orders to Nearly $900,000 for Last Five Months
11 juil. 2019 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, July 11, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today...
FINAL_LOGO-02.jpg
AXIM® Biotechnologies Signs Licensing Agreement With Leading Gum Distributor to Expand Nutraceutical Division
09 juil. 2019 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, July 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today...
FINAL_LOGO-02.jpg
AXIM® Biotechnologies Signs Supply Agreement to Register Cannabinoid Oral Care Products in Clinical Trials for Gingivitis and Gum Disease
25 juin 2019 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and development, today...
FINAL_LOGO-02.jpg
FOX Business Features Opinion Article Authored by AXIM Biotechnologies, Inc. CEO on Why Legal CBD is Good for Consumers and the Economy
05 juin 2019 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, June 05, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today...
FINAL_LOGO-02.jpg
AXIM® Biotechnologies, Inc. Signs Cannabinoid Product Supply Agreement with Healthcare Company for Clinical Trials on Treatment of Periodontitis
03 juin 2019 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today...
FINAL_LOGO-02.jpg
AXIM® Biotechnologies Announces Additional Purchase Order for Nutraceutical Product With Leading Direct Selling Company
15 mai 2019 15h29 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech”, “AXIM”, or the “Company”), a world leader in cannabinoid research and development, today...
FINAL_LOGO-02.jpg
AXIM® Biotechnologies to Present at Cannastocks 2019 Q1 Conference
14 mai 2019 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech”, “Axim”, or the “Company”), a world leader in cannabinoid research and development, today...